Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and cl

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâremitting multiple sclerosis: An 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Journal of Neurology Oct 26, 2017

Comi G, et al. - Efficacy of fingolimod and interferon beta-1b (IFN β-1b) on cognitive, magnetic resonance imaging (MRI), and clinical outcomes were evaluated during this study, in relapsingÂremitting multiple sclerosis (RRMS) patients over 18 months. The GOLDEN study confirmed the favourable benefitÂrisk profile of fingolimod reported in previous studies, although limited in size.

Go to Original

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.

4 reasons why Doctors love M3 India

Exclusive Write-ups & Webinars by KOLs
Daily Quiz by specialty
Paid Market Research Surveys
Case discussions, News & Journals' summaries

Sign-up / Log In

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâremitting multiple sclerosis: An 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâremitting multiple sclerosis: An 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)